Today is Monday, 13th February 2012

VBL Therapeutics announced positive preclinical data on the VB-201 for psoriasis – First new class of orally. . .

Last Updated on Monday, 10 May 2010 03:30 Written by databank Monday, 10 May 2010 03:30

VBL Therapeutics Announces Positive Preclinical Data For VB-201 Against Psoriasis – First In New Class Of Orally …
VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today’s data suggest that VB-201 has significant anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 …

Read more on Medical News Today


Tags: , , , , , , , , , , , , , , , , ,

This entry was posted on Monday, May 10th, 2010 at 3:30 pm and is filed under Data Bank News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Leave a Reply





Top